Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 4, 2000, Pages 279-283

  Fujita, Akihisa ^a   Takabatake, Hirotsugu ^a   Tagaki, Shigeru ^a   Sekine, Kyuhichiro ^a  

^a Minami ichijo Hospital   (Japan)

Author keywords

Irinotecan; Non small cell lung cancer; Phase I II study; RhG CSF

Indexed keywords

CISPLATIN; IFOSFAMIDE; IRINOTECAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA;

EID: 0034020346     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050041     Document Type: Article

References (12)

1. 1. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878
2. 2. Hertzberg RP, Caranfa MJ, Hecht SM (1989) On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 28: 4629-4638
3. 3. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20
4. 4. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10: 1775-1780
5. 5. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao S, Nishikawa H, Katakami N, Nakagawa K, Niitani H (1998) A phase II study of combination of CPT-11 and cisplatin for advanced non-small cell lung cancer. Br J Cancer 78: 251-256
6. 6. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N, Takada M (1994) Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12: 90-96
7. 7. Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio M, Karato A, Okamoto H, Nakashima H, Ohmatsu H, Shiraishi J, Nomura N, Saijo N (1994) Phase I clinical trial of irinotecan, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small cell lung cancer. Cancer Res 54: 2636-2642
8. 8. World Health Organization (1979) WHO handbook for reporting results of cancer treatment (WHO Offset Publication, no. 48). World Health Organization, Geneva
9. 9. Green S, Weiss G (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10: 239-253
10. 10. Fujita A, Sasaki H, Mori T, Nakajima S, Sekine K, Inoue Y, Honda R, Asakawa M, Suzuki A (1991) Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) for inoperable adenocarcinoma and large cell carcinoma of the lung. Jpn J Cancer Chemother 18: 51-55
11. 11. Fujita A, Takabatake H, Tagaki S, Sekine K (1999) Phase I study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in advanced non-small cell lung cancer. Oncology 56: 307
12. 12. Honda R, Fujita A, Inoue Y, Asakawa M, Suzuki A (1990) Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study. Cancer Chemother Pharmacol 26: 373-376